PMID- 8123866
OWN - NLM
STAT- MEDLINE
DCOM- 19940414
LR  - 20190904
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 28
IP  - 1
DP  - 1993 Oct
TI  - High DNA content and prognosis in lymph node positive breast cancer. A case 
      control study by the University of Leiden and ECOG. (Eastern Cooperative Oncology 
      Group).
PG  - 1-8
AB  - To investigate whether breast cancer cells with unusually high nuclear DNA 
      content are associated with an adverse outcome, Eastern Cooperative Oncology 
      Group investigators selected breast cancer trial patients who suffered an early 
      death (ED) within two years after diagnosis to compare with other trial patients 
      who had a survival of at least 7.5 years. Paraffin blocks of primary breast 
      cancers were obtained from 93 evaluable patients who had been enrolled in two 
      surgical adjuvant trials for lymph node positive (LN+) disease (T1-3N1M0). Single 
      cell monolayer preparations from these blocks were stained with 
      acriflavine-Feulgen and analyzed by image analysis for DNA content with the 
      automated Leiden Television Analysis System (LEY-TAS). Standard prognostic 
      variables (estrogen receptor (ER) status, number of lymph nodes with metastases, 
      and size of the cancer) were compared with three DNA content characteristics: DNA 
      ploidy status, number of nuclei with > 5C DNA content, and percent of nuclei with 
      > 5 C. Estimates of the odds ratio in multivariate comparisons showed that ER 
      negativity was associated with ED (p = 0.0005) and an odds ratio estimate using 
      negative/positive of 4.87. The number of positive lymph nodes associated with ED 
      had a p-value of 0.0005 and an odds ratio estimate of 4.63 when comparing the > 3 
      nodes group to the 1-3 nodes group. In contrast, the strongest association for 
      any of the DNA content characteristics with ED had a p-value of 0.017 and an odds 
      ratio estimate of 2.76. This power of association disappeared when stratified on 
      ER status.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Gilchrist, K W
AU  - Gilchrist KW
AD  - Wisconsin Comprehensive Cancer Center, Madison, CA 21076.
FAU - Gray, R
AU  - Gray R
FAU - van Driel-Kulker, A M
AU  - van Driel-Kulker AM
FAU - Mesker, W E
AU  - Mesker WE
FAU - Ploem-Zaaijer, J J
AU  - Ploem-Zaaijer JJ
FAU - Ploem, J S
AU  - Ploem JS
FAU - Taylor, S G
AU  - Taylor SG
FAU - Tormey, D C
AU  - Tormey DC
LA  - eng
GR  - CA 21115/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Aged
MH  - *Aneuploidy
MH  - Breast Neoplasms/*epidemiology/*genetics/mortality
MH  - Case-Control Studies
MH  - Cell Nucleus/metabolism
MH  - Clinical Trials as Topic
MH  - DNA, Neoplasm/*genetics/metabolism
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Lymphatic Metastasis
MH  - Prognosis
MH  - Prospective Studies
MH  - Television
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1007/BF00666350 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 1993 Oct;28(1):1-8. doi: 10.1007/BF00666350.